Presentation is loading. Please wait.

Presentation is loading. Please wait.

Flow of Patients Through the Trial

Published byRenzo Guerra Modified over 5 years ago

Similar presentations

Presentation on theme: "Flow of Patients Through the Trial"— Presentation transcript:

1 Flow of Patients Through the Trial
Steven E. Nissen, et al. JAMA 2006;295: Published online

2 Baseline Patient Characteristics*
Steven E. Nissen, et al. JAMA 2006;295: Published online

3 Laboratory Results (n = 346)*
Steven E. Nissen, et al. JAMA 2006;295: Published online

4 Baseline and Follow-up Intravascular Ultrasound Results
Steven E. Nissen, et al. JAMA 2006;295: Published online

5 Primary Efficacy Parameters in Prespecified Subgroups
Steven E. Nissen, et al. JAMA 2006;295: Published online

6 Adverse Events, Drug Discontinuations, and Clinical End Points in the Safety Population (N = 507)
Steven E. Nissen, et al. JAMA 2006;295: Published online

7 Example of Regression of Atherosclerosis in a Patient in the Trial
Steven E. Nissen, et al. JAMA 2006;295: Published online

8 Relationship Between Mean Low-Density Lipoprotein Cholesterol Levels and Median Change in Percent Atheroma Volume for Several Intravascular Ultrasound Trials Steven E. Nissen, et al. JAMA 2006;295: Published online

Download ppt "Flow of Patients Through the Trial"

Similar presentations

Reversing Atherosclerosis with Aggressive Lipid Lowering Reversing Atherosclerosis with Aggressive Lipid Lowering Presented at American Heart Association.

Reversing Atherosclerosis with Aggressive Lipid Lowering Reversing Atherosclerosis with Aggressive Lipid Lowering Presented at American Heart Association.
Flow chart showing number of citations retrieved by individual searches and number of trials included in review Strippoli GF, et al. BMJ 2008 Feb 25 [Epub.

Flow chart showing number of citations retrieved by individual searches and number of trials included in review Strippoli GF, et al. BMJ 2008 Feb 25 [Epub.
Montalescot G, et al. Lancet 2009;373:723-31. Trial profile Montalescot G, et al. Lancet 2009;373:723-31.

Montalescot G, et al. Lancet 2009;373: Trial profile Montalescot G, et al. Lancet 2009;373:
Trial profile Fox K et al. Lancet 2008;372:807-16.

Trial profile Fox K et al. Lancet 2008;372:
Clinical Trial Results. org Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis Stephen J. Nicholls, MBBS, PhD; E.

Clinical Trial Results. org Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis Stephen J. Nicholls, MBBS, PhD; E.
ASTEROID A Study To evaluate the Effect of Rosuvastatin On Intravascular ultrasound- Derived coronary atheroma burden.

ASTEROID A Study To evaluate the Effect of Rosuvastatin On Intravascular ultrasound- Derived coronary atheroma burden.
ASTEROID A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden   References Nissen et al. Effect.

ASTEROID A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden   References Nissen et al. Effect.
BackgroundBackground HDL-C levels are inversely related to CV event rates. HDL-C levels are inversely related to CV event rates. Torcetrapib, a cholesteryl.

BackgroundBackground HDL-C levels are inversely related to CV event rates. HDL-C levels are inversely related to CV event rates. Torcetrapib, a cholesteryl.
Slide Source: Lipids Online Slide Library www.lipidsonline.org Collaborative Atorvastatin Diabetes Study (CARDS) Type 2 diabetes mellitus Men and women.

Slide Source: Lipids Online Slide Library Collaborative Atorvastatin Diabetes Study (CARDS) Type 2 diabetes mellitus Men and women.
Comparison of the Progression of Coronary Atherosclerosis for Two High Efficacy Statin Regimens with Different HDL Effects: SATURN Study Results SJ Nicholls,

Comparison of the Progression of Coronary Atherosclerosis for Two High Efficacy Statin Regimens with Different HDL Effects: SATURN Study Results SJ Nicholls,
Flow of Participants Through the Trial David J. A. Jenkin et al. JAMA 2008;300:2742-53.

Flow of Participants Through the Trial David J. A. Jenkin et al. JAMA 2008;300:
SATURN: Objective To compare the effects of rosuvastatin 40 mg versus atorvastatin 80 mg on progression of coronary atherosclerosis assessed by intravascular.

SATURN: Objective To compare the effects of rosuvastatin 40 mg versus atorvastatin 80 mg on progression of coronary atherosclerosis assessed by intravascular.
Clinical Trial Results. org SAGE Trial Prakash Deedwania, MD; Peter H. Stone, MD; C. Noel Bairey Merz, MD; Juan Cosin-Aguilar, MD; Nevres Koylan, MD; Don.

Clinical Trial Results. org SAGE Trial Prakash Deedwania, MD; Peter H. Stone, MD; C. Noel Bairey Merz, MD; Juan Cosin-Aguilar, MD; Nevres Koylan, MD; Don.
Effect of the Renin Inhibitor Aliskiren on Progression of Coronary Atherosclerosis: AQUARIUS Study Results SJ Nicholls, GL Bakris, JJP Kastelein, V Menon,

Effect of the Renin Inhibitor Aliskiren on Progression of Coronary Atherosclerosis: AQUARIUS Study Results SJ Nicholls, GL Bakris, JJP Kastelein, V Menon,
Patient disposition Dichtl W, et al. Am J Cardiol. 2008;102:743-8 AVR = aortic valve replacement; MDCT = multidetector computed tomographic.

Patient disposition Dichtl W, et al. Am J Cardiol. 2008;102:743-8 AVR = aortic valve replacement; MDCT = multidetector computed tomographic.
Slide Source: Lipids Online Slide Library www.lipidsonline.org ASTEROID Population at Baseline (n=507) Patients Completing (n=349) Patients Not Completing.

Slide Source: Lipids Online Slide Library ASTEROID Population at Baseline (n=507) Patients Completing (n=349) Patients Not Completing.
Effect of on Oral Agent Inducing ApoA-I Synthesis on Progression of Coronary Atherosclerosis: Results of the ASSURE Study SJ Nicholls, CM Ballantyne, PJ.

Effect of on Oral Agent Inducing ApoA-I Synthesis on Progression of Coronary Atherosclerosis: Results of the ASSURE Study SJ Nicholls, CM Ballantyne, PJ.
Baseline Characteristics of the Patient Population (n=525) Colin Berry, et al. Circulation 2007;115:1851-1857.

Baseline Characteristics of the Patient Population (n=525) Colin Berry, et al. Circulation 2007;115:
Hsia J et al. J Am Coll Cardiol 2011;57:1666-75. Baseline Characteristics by Treatment Group and Attained LDL-C Hsia J et al. J Am Coll Cardiol 2011;57:1666-75.

Hsia J et al. J Am Coll Cardiol 2011;57: Baseline Characteristics by Treatment Group and Attained LDL-C Hsia J et al. J Am Coll Cardiol 2011;57:
PERISCOPE Comparison of Pioglitazone vs. Glimepiride on Progression of Coronary Atherosclerosis in Patients with Type 2 Diabetes Stephen J. Nicholls MBBS.

PERISCOPE Comparison of Pioglitazone vs. Glimepiride on Progression of Coronary Atherosclerosis in Patients with Type 2 Diabetes Stephen J. Nicholls MBBS.

Similar presentations

Ads by Google